Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.9680 +0.0194 (+2.05%)
Streaming Delayed Price Updated: 11:43 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug ↗
Via Chartmill
News headline image
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Conference Call and Live Webcast Scheduled for March 26, 2026 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Here are the top movers in Monday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 ↗
Almost all of it was event-driven, while the bulk of these gains were made by small biopharma names. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.